vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D)

Stock Information for vTv Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About vTv Therapeutics Inc.

iOnctura appoints Paul Sekhri as Chair of its Board of Directors
vTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026
vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease
vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
vTv Therapeutics to Participate in September Investor Conferences
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.